1-20 of 49
Jingqin Luo
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract PO1-06-14: Preliminary results of a phase I dose escalation study of eribulin in combination with copanlisib in patients with metastatic triple negative breast cancer (TNBC)

Nusayba Bagegni, Brittney Haas, Leslie Nehring, Jingqin Luo, Laura Kennedy, Meghna Trivedi, Manali Bhave, Rabih Said, Cynthia Ma
Journal: Cancer Research
Cancer Res (2024) 84 (9_Supplement): PO1-06-14.
https://doi.org/10.1158/1538-7445.SABCS23-PO1-06-14
Published: 02 May 2024
View article titled, Abstract PO1-06-14: Preliminary results of a phase I dose escalation study of eribulin in combination with copanlisib in patients with metastatic triple negative breast cancer (TNBC)
Journal Articles

Abstract PS17-06: A phase I trial of the PI3K inhibitor (PI3Ki) copanlisib and fulvestrant in combination with continuous or intermittent abemaciclib in patients with estrogen receptor-positive (ER+), HER2-negative (HER2-) metastatic breast cancer

Cynthia Ma, Jingqin Luo, Jessica Moss, Maryann Kwa, Ritesh Parajuli, Katia Khoury, Emily Douglas, Ashley Frith, Caron Rigden, Foluso Ademuyiwa, Shana Thomas, Brittney Haas, Gerburg Wulf, Claire Dees, Rabih Said
Journal: Cancer Research
Cancer Res (2024) 84 (9_Supplement): PS17-06.
https://doi.org/10.1158/1538-7445.SABCS23-PS17-06
Published: 02 May 2024
View article titled, Abstract PS17-06: A phase I trial of the PI3K inhibitor (PI3Ki) copanlisib and fulvestrant in combination with continuous or intermittent abemaciclib in patients with estrogen receptor-positive (ER+), HER2-negative (HER2-) metastatic breast cancer
Journal Articles

Abstract PO5-05-05: Clinical outcomes of CDK4/6 inhibitors in patients with bone only metastatic breast cancer

Mahta Mardani, Suleyman Noordeen, Katherine Clifton, Cynthia Ma, Jingqin Luo, Jing Xi, Nusayba Bagegni, Foluso Ademuyiwa, Rama Suresh, Ashley Frith, Andrew Davis, Ron Bose, Lindsay Peterson, Shana Thomas, Yu Tao, Takayuki Kobayashi, Jingyu Xiang, Yalin Xu, Xinming Su, Katherine Weilbaecher
Journal: Cancer Research
Cancer Res (2024) 84 (9_Supplement): PO5-05-05.
https://doi.org/10.1158/1538-7445.SABCS23-PO5-05-05
Published: 02 May 2024
View article titled, Abstract PO5-05-05: Clinical outcomes of CDK4/6 inhibitors in patients with bone only metastatic breast cancer
Journal Articles

Abstract 7382: Artificial intelligence derived features of collagen architecture identify high risk HPV associated oropharyngeal squamous cell carcinoma patients

Reetoja Nag, Haojia Li, Germán Corredor, Pingfu Fu, Nabil F. Saba, Mehmet A. Bilen, Tilak Pathak, Paula Toro, Mojgan Mokhtari, Krunal Pandav, Michael Gilkey, Shlomo Koyfman, Deborah Chute, Wade L. Thorstad, Mitra Mehrad, Patricia D. Castro, Andrew G. Sikora, Rebecca D. Chernock, Jingqin Luo, Mitchell Frederick, Vlad Sandulache, David J. Adelstein, James Lewis, Jr., Anant Madabhushi
Journal: Cancer Research
Cancer Res (2024) 84 (6_Supplement): 7382.
https://doi.org/10.1158/1538-7445.AM2024-7382
Published: 22 March 2024
View article titled, Abstract 7382: Artificial intelligence derived features of collagen architecture identify high risk HPV associated oropharyngeal squamous cell carcinoma patients
Journal Articles

Abstract 3429: Using metabolomics to identify biomarkers mediating the associations of adiposity in childhood and early adulthood with mammographic breast density in premenopausal women

Kayla R. Getz, Myung Sik Jeon, Lili Liu, Lei Liu, Chongliang Luo, Jingqin Luo, Adetunji T. Toriola
Journal: Cancer Research
Cancer Res (2024) 84 (6_Supplement): 3429.
https://doi.org/10.1158/1538-7445.AM2024-3429
Published: 22 March 2024
View article titled, Abstract 3429: Using metabolomics to identify biomarkers mediating the associations of adiposity in childhood and early adulthood with mammographic breast density in premenopausal women
Journal Articles

Abstract 4431: Steroid hormone metabolites and mammographic breast density in premenopausal women

Kayode A. Matthew, Girish K. Vanapali, Kayla R. Getz, Myung S. Jeon, Chongliang Luo, Xingyi Guo, Jingqin Luo, Adetunji T. Toriola
Journal: Cancer Research
Cancer Res (2024) 84 (6_Supplement): 4431.
https://doi.org/10.1158/1538-7445.AM2024-4431
Published: 22 March 2024
View article titled, Abstract 4431: Steroid hormone metabolites and mammographic breast density in premenopausal women
Journal Articles

Abstract 2140: Untargeted lipidomics reveals racial differences in lipid species among women

ang Li, Ghazaleh Pourali, Kayla R. Getz, Myung Sik Jeon, Jingqin Luo, Chongliang Luo, Adetunji T. Toriola
Journal: Cancer Research
Cancer Res (2024) 84 (6_Supplement): 2140.
https://doi.org/10.1158/1538-7445.AM2024-2140
Published: 22 March 2024
View article titled, Abstract 2140: Untargeted lipidomics reveals racial differences in lipid species among women
Journal Articles

Abstract 3803: The landscape of circular RNAs in metastatic colorectal cancer

Sidi Zhao, Amy Ly, Jacqueline L. Mudd, Emily B. Rozycki, Ghofran Othoum, Jingqin Luo, Ha X. Dang, Ryan C. Fields, Christopher A. Maher
Journal: Cancer Research
Cancer Res (2023) 83 (7_Supplement): 3803.
https://doi.org/10.1158/1538-7445.AM2023-3803
Published: 04 April 2023
View article titled, Abstract 3803: The landscape of circular RNAs in metastatic colorectal cancer
Journal Articles

Abstract 4271: A new methodological approach to discovering biomarkers of mammographic breast density using pathway-guided lipid amalgamation

Chongliang Luo, Jingqin Luo, Kayla R. Getz, Myung Sik Jeon, Adetunji T. Toriola
Journal: Cancer Research
Cancer Res (2023) 83 (7_Supplement): 4271.
https://doi.org/10.1158/1538-7445.AM2023-4271
Published: 04 April 2023
View article titled, Abstract 4271: A new methodological approach to discovering biomarkers of mammographic breast density using pathway-guided lipid amalgamation
Journal Articles

Abstract 4173: Lipidome of mammographic breast density in premenopausal women

Kayla R. Getz, Myung S. Jeon, Chongliang Luo, Jingqin Luo, Adetunji T. Toriola
Journal: Cancer Research
Cancer Res (2023) 83 (7_Supplement): 4173.
https://doi.org/10.1158/1538-7445.AM2023-4173
Published: 04 April 2023
View article titled, Abstract 4173: Lipidome of mammographic breast density in premenopausal women
Journal Articles

Abstract PD13-09: PD13-09 Clinical outcomes of patients with HR+ HER2- advanced breast cancer with early progression on CDK4/6 inhibitors

Katherine K. Clifton, Shana N. Thomas, Jingqin Luo, Jing Xi, Nusayba A. Bagegni, Foluso O. Ademuyiwa, Rama Suresh, Ashley Frith, Andrew A. Davis, Ron Bose, Katherine Weilbaecher, Whitney L. Hensing, Timothy Pluard, Massimo Cristofanilli, Hyo S. Han, Adam M. Brufsky, Kevin Kalinsky, Shom Goel, Seth A. Wander, Lindsay L. Peterson, Cynthia Ma
Journal: Cancer Research
Cancer Res (2023) 83 (5_Supplement): PD13-09.
https://doi.org/10.1158/1538-7445.SABCS22-PD13-09
Published: 01 March 2023
View article titled, Abstract PD13-09: PD13-09 Clinical outcomes of patients with HR+ HER2- advanced breast cancer with early progression on CDK4/6 inhibitors
Journal Articles

Abstract PD12-09: PD12-09 Serum Advanced Glycation End-Products are Associated with Breast Cancer Prognosis

Lindsay L. Peterson, Yu Tao, Jingqin Luo, Graham A. Colditz, Yikyung Park, Jennifer A. Ligibel, David Turner
Journal: Cancer Research
Cancer Res (2023) 83 (5_Supplement): PD12-09.
https://doi.org/10.1158/1538-7445.SABCS22-PD12-09
Published: 01 March 2023
View article titled, Abstract PD12-09: PD12-09 Serum Advanced Glycation End-Products are Associated with Breast Cancer Prognosis
Journal Articles

Abstract P3-06-07: Phase Ib/II study to evaluate safety and tolerability of cabiralizumab in combination with nivolumab and neoadjuvant chemotherapy in patients with localized triple-negative breast cancer

Andrew A. Davis, Leonel Hernandez-Aya, Jingqin Luo, Mateusz Opyrchal, Foluso O. Ademuyiwa, Nusayba A. Bagegni, Katherine K. Clifton, Jill Anderson, Trish Hammerschmidt, Leslie Nehring, David DeNardo, Mark Watson, Rebecca Aft, Cynthia Ma, Katherine Weilbaecher
Journal: Cancer Research
Cancer Res (2023) 83 (5_Supplement): P3-06-07.
https://doi.org/10.1158/1538-7445.SABCS22-P3-06-07
Published: 01 March 2023
View article titled, Abstract P3-06-07: Phase Ib/II study to evaluate safety and tolerability of cabiralizumab in combination with nivolumab and neoadjuvant chemotherapy in patients with localized triple-negative breast cancer
Journal Articles

Abstract OT3-11-01: TK IMPACT: Treatment Monitoring of Hormone Receptor Positive (HR+), HER2 Negative (HER2-) Metastatic Breast Cancer (MBC) Patients Receiving CDK 4/6 Inhibitors (CDK4/6i) with DiviTum® Thymidine Kinase 1 Activity

Nusayba A. Bagegni, Isabella Grigsby, Leslie Nehring, Jingqin Luo, Jennifer Powers Carson, David W. Gibson, Meghan Horvath, Katherine K. Clifton, Foluso O. Ademuyiwa, Rama Suresh, Ashley Frith, Andrew A. Davis, Lindsay L. Peterson, Ron Bose, Amy Williams, Mattias Bergqvist, Cynthia Ma
Journal: Cancer Research
Cancer Res (2023) 83 (5_Supplement): OT3-11-01.
https://doi.org/10.1158/1538-7445.SABCS22-OT3-11-01
Published: 01 March 2023
View article titled, Abstract OT3-11-01: TK IMPACT: Treatment Monitoring of Hormone Receptor Positive (HR+), HER2 Negative (HER2-) Metastatic Breast Cancer (MBC) Patients Receiving CDK 4/6 Inhibitors (CDK4/6i) with DiviTum® Thymidine Kinase 1 Activity
Journal Articles

Abstract GS4-07: The Breast PreCancer Atlas DCIS genomic signatures define biology and correlate with clinical outcomes: An analysis of TBCRC 038 and RAHBT cohorts

Siri H Strand, Belén Rivero-Gutiérrez, Kathleen E Houlahan, Jose A Seoane, Lorraine M King, Tyler Risom, Lunden Simpson, Sujay Vennam, Aziz Khan, Timothy Hardman, Bryan E Harmon, Fergus J Couch, Kristalyn Gallagher, Mark Kilgore, Shi Wei, Angela DeMichele, Tari King, Priscilla F McAuliffe, Julie Nangia, Joanna Lee, Jennifer Tseng, Anna Maria Storniolo, Alastair Thompson, Gaorav Gupta, Robyn Burns, Deborah J Veis, Katherine DeSchryver, Chunfang Zhu, Magdalena Matusiak, Jason Wang, Shirley X Zhu, Jen Tappenden, Daisy Yi Ding, Dadong Zhang, Jingqin Luo, Shu Jiang, Sushama Varma, Cody Straub, Sucheta Srivastava, Christina Curtis, Rob Tibshirani, Robert Michael Angelo, Allison Hall, Kouros Owzar, Kornelia Polyak, Carlo Maley, Jeffrey R Marks, Graham A Colditz, E Shelley Hwang, Robert B West
Journal: Cancer Research
Cancer Res (2022) 82 (4_Supplement): GS4-07.
https://doi.org/10.1158/1538-7445.SABCS21-GS4-07
Published: 15 February 2022
View article titled, Abstract GS4-07: The Breast PreCancer Atlas DCIS genomic signatures define biology and correlate with clinical outcomes: An analysis of TBCRC 038 and RAHBT cohorts
Journal Articles

Abstract P2-07-01: Blood tumor mutational burden (bTMB) and blood copy number burden (bCNB) by genome-wide circulating tumor DNA (ctDNA) assessment predict outcome and resistance in hormone-receptor positive (HR+), HER2 negative (HER2-) metastatic breast cancer (MBC) patients (pts) treated with CDK4/6 inhibitor (CDK4/6i)

Andrew Davis, Jingqin Luo, Tiantian Zheng, Lu Tan, Amy Wang, Rama Suresh, Foluso Ademuyiwa, Caron Rigden, Timothy Rearden, Katherine Clifton, Katherine Weilbaecher, Ashley Frith, Pavan K Tandra, Tracy Summa, Brittney Haas, Shana Thomas, Leonel Hernandez-Aya, Lindsay Peterson, Shujun Luo, Bonnie L King, Shidong Jia, Jianjun Yu, Pan Du, Jairam Krishnamurthy, Cynthia X Ma, C Dai
Journal: Cancer Research
Cancer Res (2022) 82 (4_Supplement): P2-07-01.
https://doi.org/10.1158/1538-7445.SABCS21-P2-07-01
Published: 15 February 2022
View article titled, Abstract P2-07-01: Blood tumor mutational burden (bTMB) and blood copy number burden (bCNB) by genome-wide circulating tumor DNA (ctDNA) assessment predict outcome and resistance in hormone-receptor positive (HR+), HER2 negative (HER2-) metastatic breast cancer (MBC) patients (pts) treated with CDK4/6 inhibitor (CDK4/6<em>i</em>)
Journal Articles

Abstract P3-09-04: Genomic landscape of HER2-negative advanced or metastatic breast cancer with PIK3CA gain-of-function mutations

Jing Xi, Kathleen Harnden, Jingqin Luo, Greg S. Call, Elizabeth Mauer, Karyn Ronski, Cynthia X. Ma, Neil Vasan
Journal: Cancer Research
Cancer Res (2022) 82 (4_Supplement): P3-09-04.
https://doi.org/10.1158/1538-7445.SABCS21-P3-09-04
Published: 15 February 2022
View article titled, Abstract P3-09-04: Genomic landscape of HER2-negative advanced or metastatic breast cancer with PIK3CA gain-of-function mutations
Journal Articles

Abstract P2-13-01: Phase 2 study of neoadjuvant palbociclib, letrozole, and trastuzumab in patients with ER+ HER2+ breast cancer (PALTAN)

Foluso O Ademuyiwa, Donald Northfelt, Tracey O'Connor, Ellis Levine, Jingqin Luo, Yu Tao, Jeremy Hoog, Marie Laury, Tracy Summa, Trish Hammerschmidt, Zhanfang Guo, Ashley Frith, Katherine Weilbaecher, Mateusz Opyrchal, Rebecca Aft, Katherine Clifton, Rama Suresh, Nusayba Bagegni, Ian S Hagemann, Cynthia X Ma
Journal: Cancer Research
Cancer Res (2022) 82 (4_Supplement): P2-13-01.
https://doi.org/10.1158/1538-7445.SABCS21-P2-13-01
Published: 15 February 2022
View article titled, Abstract P2-13-01: Phase 2 study of neoadjuvant palbociclib, letrozole, and trastuzumab in patients with ER+ HER2+ breast cancer (PALTAN)
Journal Articles

Loss of Long Noncoding RNA NXTAR in Prostate Cancer Augments Androgen Receptor Expression and Enzalutamide Resistance

Ruchi Ghildiyal, Mithila Sawant, Arun Renganathan, Kiran Mahajan, Eric H. Kim, Jingqin Luo, Ha X. Dang, Christopher A. Maher, Felix Y. Feng, Nupam P. Mahajan
Journal: Cancer Research
Cancer Res (2022) 82 (1): 155–168.
https://doi.org/10.1158/0008-5472.CAN-20-3845
Published: 04 January 2022
View article titled, Loss of Long Noncoding RNA <em>NXTAR</em> in Prostate Cancer Augments Androgen Receptor Expression and Enzalutamide Resistance
Open the PDF for Loss of Long Noncoding RNA <em>NXTAR</em> in Prostate Cancer Augments Androgen Receptor Expression and Enzalutamide Resistance in another window
Includes: Supplementary data
Journal Articles

Abstract CT026: A phase II trial of neratinib (NER) or NER plus fulvestrant (FUL) (N+F) in HER2 mutant, non-amplified (HER2mut) metastatic breast cancer (MBC): Part II of MutHER

Cynthia X. Ma, Jingqin Luo, Rachel A. Freedman, Timothy Pluard, Julie Nangia, Janice Lu, Frances Valdez-Albini, Melody Cobleigh, Jason Jones, Nancy U. Lin, Eric Winer, P. Kelly Marcom, Shana Thomas, Jill Anderson, Brittney Haas, Kimberly M. Hamann, Richard Bryce, Alshad S. Lalani, Lisa Carey, Matthew Goetz, Feng Gao, Gretchen Kimmick, Mark Pegram, Matthew J. Ellis, Ron Bose
Journal: Cancer Research
Cancer Res (2021) 81 (13_Supplement): CT026.
https://doi.org/10.1158/1538-7445.AM2021-CT026
Published: 01 July 2021
View article titled, Abstract CT026: A phase II trial of neratinib (NER) or NER plus fulvestrant (FUL) (N+F) in HER2 mutant, non-amplified (HER2mut) metastatic breast cancer (MBC): Part II of MutHER